Wells Fargo Maintains Equal-Weight on CRISPR Therapeutics, Lowers Price Target to $70
Wells Fargo analyst Yanan Zhu maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Equal-Weight and lowers the price target from $75 to $70.
Share
Why It Matters
An expert thinks CRISPR stock is fairly priced, not a great buy or sell. They lowered their target price a bit, suggesting they see less upside ahead.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.